Basics

Who Qualifies for GLP-1 Medications? BMI, Eligibility & Requirements

GLP-1 Companion · 6 min read

The wrong way to research GLP-1 access is to start with "where can I buy it?" The right first question is "do I plausibly qualify, and what kind of clinician should evaluate me?" Eligibility depends on FDA criteria, insurance requirements, contraindications, and your individual health history.

My position: do not pay a platform fee until you know which eligibility path you are on: weight-management indication, type 2 diabetes indication, cardiovascular/OSA-related indication, or a case where GLP-1 may not be appropriate. That single distinction changes medication choice, insurance odds, and total cost.

FDA Eligibility Criteria for Weight Management

For GLP-1 medications approved for chronic weight management, such as Wegovy and Zepbound, the FDA has established clear eligibility thresholds based on body mass index (BMI):

• BMI of 30 or greater (obesity): You qualify based on BMI alone.
• BMI of 27 or greater (overweight) with at least one weight-related comorbidity: Eligible conditions include type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease.

These criteria apply to adults aged 18 and older. Wegovy has also been approved for adolescents aged 12 and older with a BMI at or above the 95th percentile for their age and sex.

FDA Eligibility for Type 2 Diabetes

GLP-1 medications approved for type 2 diabetes, such as Ozempic, Mounjaro, and Trulicity, are indicated for adults with a confirmed diagnosis of type 2 diabetes to improve glycemic control. There is no specific BMI requirement for the diabetes indication, although most patients with type 2 diabetes do have elevated BMI.

Insurance Eligibility: Beyond the FDA Label

Meeting FDA criteria does not guarantee insurance coverage. Most insurance companies impose their own additional requirements before approving a GLP-1 prescription. These vary by plan but commonly include:

1. Documented history of trying diet and exercise programs for a specified period (usually 3 to 6 months).
2. Failure of at least one prior weight loss medication, such as phentermine or orlistat.
3. A letter of medical necessity from your prescribing physician.
4. Prior authorization approval before the prescription is filled.
5. Ongoing documentation of weight loss progress at regular intervals.

Weight-Related Comorbid Conditions That Support Eligibility

If your BMI falls between 27 and 30, you will need at least one qualifying comorbid condition to be eligible. The following conditions are commonly accepted:

• Type 2 diabetes or prediabetes
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease
• Nonalcoholic fatty liver disease (NAFLD)
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis related to excess weight

Who Should NOT Take GLP-1 Medications

There are specific contraindications that make GLP-1 medications unsafe for certain individuals. Your doctor will screen for these before prescribing.

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis (use with caution or avoid)
• Severe gastrointestinal disease, including gastroparesis
• Pregnancy or planned pregnancy (GLP-1 medications should be stopped at least 2 months before conception)
• Known hypersensitivity to the active ingredient or any component of the formulation
• Type 1 diabetes (GLP-1 RAs are not approved for type 1 diabetes)

How to Talk to Your Doctor About GLP-1 Medications

If you believe you may qualify for a GLP-1 medication, scheduling a conversation with your healthcare provider is the essential first step. Here is how to prepare for a productive discussion:

1. Know your numbers. Check your current BMI, blood pressure, fasting blood sugar, and cholesterol levels before your appointment.
2. Document your weight history. Bring records of previous weight loss attempts, including any structured programs or medications you have tried.
3. List your health conditions. Write down all diagnosed conditions, especially those related to excess weight.
4. Research your insurance coverage. Call your insurer or check your plan documents to understand whether obesity medications are covered and what prior authorization requirements exist.
5. Ask specific questions. Inquire about which GLP-1 medication your doctor recommends, the expected timeline, and how side effects will be managed.

Obesity is a chronic medical condition, not a character flaw. You deserve evidence-based treatment just as you would for any other health condition. Do not hesitate to advocate for yourself with your healthcare team.

What If You Do Not Meet the BMI Threshold?

If your BMI is below 27, you currently do not meet the FDA criteria for weight management GLP-1 medications. However, if you have type 2 diabetes, you may still qualify for diabetes-indicated GLP-1 drugs regardless of your BMI. Additionally, research into lower-BMI applications of these medications is ongoing, and eligibility criteria may evolve as new clinical data emerges.

For individuals who do not qualify, focusing on nutrition, physical activity, sleep, and stress management remains the most effective approach to healthy weight management. A registered dietitian or obesity medicine specialist can help create a personalized plan.

Key Takeaways

• A BMI of 30 or higher qualifies you for weight management GLP-1 medications; a BMI of 27 or higher qualifies you if you also have a weight-related comorbidity.
• Insurance companies often require documentation of prior weight loss attempts before covering these medications.
• Certain medical conditions, including medullary thyroid carcinoma and pregnancy, are absolute contraindications.
• Preparing for your doctor visit with relevant health data and insurance information will help you get the best outcome.

The practical next step is simple: calculate BMI, collect your condition and medication history, check insurance coverage, then choose a clinician or partner platform that can review the full case before anything is prescribed.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.